KRAS and neoplasm: CD8+ T-cells against mutant KRAS G12D obtained from tumor-infiltrating lymphocytes (TILs) of a patient with metastatic colorectal cancer were reinfused at 1.11 × 1011 into the patient, resulting in regression of metastatic colon cancer after therapy41.